tranexamic acid has been researched along with Thromboembolism in 117 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Thromboembolism: Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Tranexamic acid (TXA) is an antifibrinolytic drug potentially limiting hematoma expansion." | 9.69 | Tranexamic Acid for Intracerebral Hemorrhage in Patients on Non-Vitamin K Antagonist Oral Anticoagulants (TICH-NOAC): A Multicenter, Randomized, Placebo-Controlled, Phase 2 Trial. ( Barinka, F; Baumgartner, P; Bonati, LH; De Marchis, GM; Engelter, ST; Fischer, U; Gensicke, H; Guzman, R; Kägi, G; Karwacki, GM; Lyrer, PA; Maurer, M; Nedeltchev, K; Nickel, CH; Peters, N; Polymeris, AA; Schaedelin, S; Seiffge, DJ; Siepen, BM; Sprigg, N; Stippich, C; Thilemann, S; Traenka, C; Tsakiris, DA; Vehoff, J; Wagner, B; Wegener, S; Z'Graggen, WJ, 2023) |
| "Screening for the risk of thromboembolism (TE) due to tranexamic acid (TXA) in patients with severe traumatic injury has not been performed in randomized clinical trials." | 9.51 | The risk of thromboembolic events with early intravenous 2- and 4-g bolus dosing of tranexamic acid compared to placebo in patients with severe traumatic bleeding: A secondary analysis of a randomized, double-blind, placebo-controlled, single-center trial ( Bochicchio, G; Bochicchio, K; Cap, AP; Levy, JH; Pusateri, AE; Schuerer, D; Shea, SM; Spinella, PC; Staudt, A; Thomas, KA, 2022) |
| "Meta-analyses on the use of tranexamic acid (TXA) in intertrochanteric fractures have shown inconsistent results due to variations in inclusion criteria and clinical heterogeneity." | 9.41 | Intravenous application of tranexamic acid in intramedullary nailing for the treatment of geriatric intertrochanteric fractures: a systematic review and meta-analysis. ( Fan, X; Wu, J; Yuan, X; Zhang, J; Zheng, Y, 2023) |
| "To assess whether a policy of routine administration of high-dose tranexamic acid (TA) at the diagnosis of postpartum hemorrhage (PPH) reduces blood loss after vaginal birth." | 9.22 | Policy of high-dose tranexamic acid for treating postpartum hemorrhage after vaginal delivery. ( Bouet, PE; Descamps, P; Gillard, P; Legendre, G; Ruiz, V; Sentilhes, L, 2016) |
| "This study aimed to evaluate the efficacy and safety of using high-dose intravenous tranexamic acid (TXA) to reduce blood loss in idiopathic scoliosis surgery." | 9.12 | The efficacy and safety of high-dose tranexamic acid in adolescent idiopathic scoliosis: a meta-analysis. ( Chen, JC; Lin, L; Na, XQ; Qu, QC; Ruan, TY; Shrestha, IK; Si, YY; Tan, M; Tao, JP, 2021) |
| "To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in people with haematological disorders." | 8.93 | Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. ( Brunskill, SJ; Desborough, M; Doree, C; Estcourt, LJ; Hopewell, S; Murphy, MF; Stanworth, SJ, 2016) |
| "Intravenous tranexamic acid safely reduces risk of hematoma in implant-based breast reconstruction." | 7.96 | Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events. ( Banuelos, J; Harless, CA; Jacobson, SR; Manrique, OJ; Martinez-Jorge, J; Nguyen, MT; Tran, NV; Weissler, JM, 2020) |
| "The major concern with the use of tranexamic acid is that it may promote a hypercoagulable state and increase the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly when chemical thromboprophylaxis is not used." | 7.85 | Chemical Thromboprophylaxis Is Not Necessary to Reduce Risk of Thromboembolism With Tranexamic Acid After Total Hip Arthroplasty. ( Kim, JS; Kim, YH; Park, JW, 2017) |
| "Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e." | 7.68 | Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993) |
| "Tranexamic acid is an antifibrinolytic drug that is widely used during surgery, but there are concerns about its thromboembolic effects." | 7.01 | Prophylactic intravenous tranexamic acid and thromboembolism in non-cardiac surgery: a systematic review, meta-analysis and trial sequential analysis. ( Cheah, S; Cheong, CC; Mong, SXY; Ng, KT; Tsan, SEH; Viknaswaran, NL; Wang, CY, 2023) |
| " Tranexamic acid (TXA) is an antifibrinolytic drug potentially limiting hematoma expansion." | 5.69 | Tranexamic Acid for Intracerebral Hemorrhage in Patients on Non-Vitamin K Antagonist Oral Anticoagulants (TICH-NOAC): A Multicenter, Randomized, Placebo-Controlled, Phase 2 Trial. ( Barinka, F; Baumgartner, P; Bonati, LH; De Marchis, GM; Engelter, ST; Fischer, U; Gensicke, H; Guzman, R; Kägi, G; Karwacki, GM; Lyrer, PA; Maurer, M; Nedeltchev, K; Nickel, CH; Peters, N; Polymeris, AA; Schaedelin, S; Seiffge, DJ; Siepen, BM; Sprigg, N; Stippich, C; Thilemann, S; Traenka, C; Tsakiris, DA; Vehoff, J; Wagner, B; Wegener, S; Z'Graggen, WJ, 2023) |
| "Screening for the risk of thromboembolism (TE) due to tranexamic acid (TXA) in patients with severe traumatic injury has not been performed in randomized clinical trials." | 5.51 | The risk of thromboembolic events with early intravenous 2- and 4-g bolus dosing of tranexamic acid compared to placebo in patients with severe traumatic bleeding: A secondary analysis of a randomized, double-blind, placebo-controlled, single-center trial ( Bochicchio, G; Bochicchio, K; Cap, AP; Levy, JH; Pusateri, AE; Schuerer, D; Shea, SM; Spinella, PC; Staudt, A; Thomas, KA, 2022) |
| " TXA dosage groups were divided into ≤10mg/kg, >10-25mg/kg and >25-50mg/kg." | 5.46 | Combined intravenous, topical and oral tranexamic acid administration in total knee replacement: Evaluation of safety in patients with previous thromboembolism and effect on hemoglobin level and transfusion rate. ( Jansen, JA; Lameijer, JRC; Snoeker, BAM, 2017) |
| "Tranexamic acid (TXA) is an antifibrinolytic that reduces blood loss after THA and TKA." | 5.43 | Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid. ( Campbell, JC; Mirocha, JM; Sharfman, ZT; Spitzer, AI, 2016) |
| " We conclude that the intraarticular administration of TXA may be a safe and effective alternative for patients who have contraindications against intravenous TXA." | 5.43 | Intraarticular Administration of Tranexamic Acid is Safe and Effective in Total Knee Arthroplasty Patients at High-Risk for Thromboembolism. ( Chughtai, M; Delanois, RE; Gwam, C; Khlopas, A; Mistry, JB; Mont, MA; Mudaliar, PP; Tangri, V; Thomas, M, 2016) |
| "Tranexamic acid (TXA) has been used to reduce blood loss during total hip arthroplasty (THA), but its use could increase the risk of venous thromboembolic disease (VTE)." | 5.42 | Does tranexamic acid alter the risk of thromboembolism after total hip arthroplasty in the absence of routine chemical thromboprophylaxis? ( Hamada, M; Nishihara, S, 2015) |
| "Meta-analyses on the use of tranexamic acid (TXA) in intertrochanteric fractures have shown inconsistent results due to variations in inclusion criteria and clinical heterogeneity." | 5.41 | Intravenous application of tranexamic acid in intramedullary nailing for the treatment of geriatric intertrochanteric fractures: a systematic review and meta-analysis. ( Fan, X; Wu, J; Yuan, X; Zhang, J; Zheng, Y, 2023) |
| "Among women with vaginal delivery who received prophylactic oxytocin, the use of tranexamic acid did not result in a rate of postpartum hemorrhage of at least 500 ml that was significantly lower than the rate with placebo." | 5.27 | Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery. ( Azria, E; Bohec, C; Chrétien, JM; Daniel, V; Darsonval, A; Deneux-Tharaux, C; Deruelle, P; Desbrière, R; Doret-Dion, M; Ducarme, G; Fuchs, F; Huissoud, C; Kayem, G; Le Ray, C; Perrotin, F; Seco, A; Sénat, MV; Sentilhes, L; Vardon, D; Winer, N, 2018) |
| "Tranexamic acid is widely available and used off-label in patients with bleeding traumatic injury, although the literature does not consistently agree on its efficacy and safety." | 5.22 | Association of Tranexamic Acid Administration With Mortality and Thromboembolic Events in Patients With Traumatic Injury: A Systematic Review and Meta-analysis. ( Hess, S; Karl, V; Maegele, M; Mathes, T; Thorn, S, 2022) |
| "To assess whether a policy of routine administration of high-dose tranexamic acid (TA) at the diagnosis of postpartum hemorrhage (PPH) reduces blood loss after vaginal birth." | 5.22 | Policy of high-dose tranexamic acid for treating postpartum hemorrhage after vaginal delivery. ( Bouet, PE; Descamps, P; Gillard, P; Legendre, G; Ruiz, V; Sentilhes, L, 2016) |
| "This study aimed to evaluate the efficacy and safety of using high-dose intravenous tranexamic acid (TXA) to reduce blood loss in idiopathic scoliosis surgery." | 5.12 | The efficacy and safety of high-dose tranexamic acid in adolescent idiopathic scoliosis: a meta-analysis. ( Chen, JC; Lin, L; Na, XQ; Qu, QC; Ruan, TY; Shrestha, IK; Si, YY; Tan, M; Tao, JP, 2021) |
| "To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in people with haematological disorders." | 4.93 | Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. ( Brunskill, SJ; Desborough, M; Doree, C; Estcourt, LJ; Hopewell, S; Murphy, MF; Stanworth, SJ, 2016) |
| "We present a case of cardiopulmonary arrest secondary to rivaroxaban related oropharyngeal hemorrhage, which required rapid intravenous (IV) push administration of 4-factor prothrombin complex concentrate (4F-PCC)." | 4.31 | Rapid administration of Kcentra® during cardiopulmonary arrest. ( Cocchio, C; Gagnon, Z; White, K, 2023) |
| " The PBM protocol consisted of epoetin (EPO) alfa therapy prescribed by the surgeon, routine administration of tranexamic acid (TXA), an avascular approach to the hip and postoperative prophylaxis of thromboembolism." | 4.02 | Application of an adjusted patient blood management protocol in patients undergoing elective total hip arthroplasty: towards a zero-percent transfusion rate in renal patients-results from an observational cohort study. ( Fennema, P; Hourlier, H, 2021) |
| "Intravenous tranexamic acid safely reduces risk of hematoma in implant-based breast reconstruction." | 3.96 | Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events. ( Banuelos, J; Harless, CA; Jacobson, SR; Manrique, OJ; Martinez-Jorge, J; Nguyen, MT; Tran, NV; Weissler, JM, 2020) |
| "The CRASH-2 trial demonstrated that tranexamic acid (TXA) in adults with significant traumatic hemorrhage safely reduces mortality." | 3.96 | Mortality and Complication Rates in Adult Trauma Patients Receiving Tranexamic Acid: A Single-center Experience in the Post-CRASH-2 Era. ( Benipal, S; Erramouspe, PJ; Galante, JM; García-Pintos, MF; Manoukian, MAC; Nishijima, D; Santamarina, JL; Shawagga, HG; Vo, LL, 2020) |
| "The present study aimed to examine the association between tranexamic acid use and adverse effects (seizures, thromboembolism, and renal dysfunction) in a pediatric trauma population using a national inpatient database in Japan." | 3.88 | Safety of Tranexamic Acid During Pediatric Trauma: A Nationwide Database Study. ( Maeda, T; Matsui, H; Michihata, N; Miyata, S; Ohnishi, Y; Sasabuchi, Y; Yasunaga, H, 2018) |
| "The major concern with the use of tranexamic acid is that it may promote a hypercoagulable state and increase the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly when chemical thromboprophylaxis is not used." | 3.85 | Chemical Thromboprophylaxis Is Not Necessary to Reduce Risk of Thromboembolism With Tranexamic Acid After Total Hip Arthroplasty. ( Kim, JS; Kim, YH; Park, JW, 2017) |
| "Rivaroxaban is a direct factor Xa inhibitor approved for prevention of stroke, prevention and treatment of venous thromboembolism and secondary prevention of acute coronary syndrome in many countries." | 3.80 | Monitoring the anticoagulant effect after a massive rivaroxaban overdose. ( Linkins, LA; Moffat, K, 2014) |
| "This case report discusses enucleation of a central dentigerous cyst in a 72-year old male on long-term low dose aspirin therapy." | 3.78 | Management of a dentigerous cyst in a medically compromised geriatric patient: a case report. ( Bains, R; Bains, VK; Loomba, A; Loomba, K, 2012) |
| "Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e." | 3.68 | Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993) |
| "Tranexamic acid is an antifibrinolytic drug that is widely used during surgery, but there are concerns about its thromboembolic effects." | 3.01 | Prophylactic intravenous tranexamic acid and thromboembolism in non-cardiac surgery: a systematic review, meta-analysis and trial sequential analysis. ( Cheah, S; Cheong, CC; Mong, SXY; Ng, KT; Tsan, SEH; Viknaswaran, NL; Wang, CY, 2023) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug associated with reduced blood loss in a range of surgical specialties, including neurosurgery, orthopedic surgery, and cardiac surgery." | 3.01 | Systematic review and meta-analysis of topical tranexamic acid in spine surgery. ( Ambati, VS; Chan, AK; Chou, D; Izima, C; Sampath, SG; Tang, AJ, 2023) |
| "Osteoporotic hip fractures are a major health problem in developed countries." | 3.01 | Intravenous tranexamic acid and thromboembolic events in hip fracture surgery: A systematic review and meta-analysis. ( Leverett, GD; Marriott, A, 2023) |
| "Tranexamic acid (TXA) has been shown to be effective in reducing blood loss after total knee replacement." | 2.94 | Topical tranexamic acid in cemented primary total knee arthroplasty without tourniquet: a prospective randomized study. ( Bustamante Suarez de Puga, D; Martínez Gimenez, E; Mas Martinez, J; Morales Santias, M; Sanz-Reig, J; Verdu Román, C, 2020) |
| "Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98)." | 2.94 | Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. ( , 2020) |
| "Tranexamic acid (TXA) reduces surgical blood loss and alleviates inflammatory response in total hip arthroplasty." | 2.90 | Effect of Multiple Doses of Oral Tranexamic Acid on Haemostasis and Inflammatory Reaction in Total Hip Arthroplasty: A Randomized Controlled Trial. ( He, C; Li, Q; Luo, ZY; Pei, FX; Wang, D; Yang, Y; Zeng, WN; Zhou, ZK, 2019) |
| "However, pulmonary embolism was statistically more frequent in 'TXA' group (11." | 2.90 | Benefits of the tranexamic acid in head trauma with no extracranial bleeding: a prospective follow-up of 180 patients. ( Bouaziz, M; Chakroun-Walha, O; Chtara, K; Jerbi, M; Kanoun, H; Ksibi, H; Nasri, A; Rekik, N; Samet, A; Souissi, B; Talbi, A, 2019) |
| " Also, TXA had similar efficacy and safety profiles in patients with different frequency and dosage of TXA." | 2.82 | Tranexamic acid usage in hip fracture surgery: a meta-analysis and meta-regression analysis of current practice. ( Deng, S; Liang, J; Liu, W, 2022) |
| " Data on the study setting, injury type, participants, design, interventions, TXA dosing and outcomes were extracted." | 2.82 | Effectiveness and safety of tranexamic acid in pediatric trauma: A systematic review and meta-analysis. ( Finkelstein, Y; Gill, PJ; Kornelsen, E; Kuppermann, N; Nishijima, DK; Ren, LY; Rumantir, M, 2022) |
| " Moreover, TXA use is safe in terms of incidence of symptomatic DVT and TE." | 2.82 | Combined Administration of Systemic and Topical Tranexamic Acid for Total Knee Arthroplasty: Can It Be a Better Regimen and Yet Safe? A Randomized Controlled Trial. ( Jain, NP; Nisthane, PP; Shah, NA, 2016) |
| "Transfusion therapy in hemorrhaging trauma patients is associated with the development of thromboembolic events." | 2.66 | The impact of blood product ratio and procoagulant therapy on the development of thromboembolic events in severely injured hemorrhaging trauma patients. ( Goslings, JC; Juffermans, NP; Schalkers, DV; Wirtz, MR, 2020) |
| "Tranexamic acid (TXA) is an anti-fibrinolytic agent that acts by inhibiting plasminogen activation and fibrinolysis." | 2.66 | The never ending success story of tranexamic acid in acquired bleeding. ( Franchini, M; Mannucci, PM, 2020) |
| " Meta-analysis showed that systemic TXA did not increase risk of adverse events compared to placebo or no intervention (relative risk, 1." | 2.61 | Exclusion criteria and adverse events in perioperative trials of tranexamic acid: a systematic review and meta-analysis. ( Khair, S; Lampron, J; Perelman, I; Saidenberg, E; Taylor, J; Tinmouth, A; Yates, J, 2019) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug widely used as a blood-sparing technique in total knee arthroplasty (TKA), and it is usually administrated by intravenous or intraarticular injection." | 2.58 | Efficacy and safety of oral tranexamic acid in total knee arthroplasty: A systematic review and meta-analysis. ( Cheng, L; Gao, F; Guo, P; Guo, W; He, Z; Li, Z; Sun, W; Wang, Y, 2018) |
| "Prostate cancer and benign prostatic hyperplasia have an increased incidence with aging." | 2.58 | Systematic review and meta-analyses of tranexamic acid use for bleeding reduction in prostate surgery. ( Cavalheiro, BT; de Oliveira Filho, GR; Longo, MA, 2018) |
| " However, still further studies are needed to identify the optimal route of administration, TXA dosage and timing." | 2.58 | A systematic review of tranexamic acid usage in patients undergoing femoral fracture surgery. ( Bai, J; Chen, P; He, J; Liang, Y; Wang, J; Zhang, P, 2018) |
| "Tranexamic acid (TXA) has been proven to be effective in reducing blood loss and transfusion rate after total knee arthroplasty (TKA) without increasing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE)." | 2.55 | Is combined use of intravenous and intraarticular tranexamic acid superior to intravenous or intraarticular tranexamic acid alone in total knee arthroplasty? A meta-analysis of randomized controlled trials. ( Liu, G; Liu, J; Liu, Y; Lv, H; Mi, B; Wu, Q; Zha, K, 2017) |
| "Ovarian cancer is the third most common gynaecological cancer worldwide, with an age-standardised incidence rate of 6." | 2.53 | Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer. ( Kietpeerakool, C; Laopaiboon, M; Lumbiganon, P; Supoken, A, 2016) |
| " Therefore, thromboembolic risk and tranexamic acid dosage should be carefully evaluated." | 2.53 | [Tranexamic acid for upper gastrointestinal bleeding]. ( Fenger-Eriksen, C; Jessing, TD, 2016) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug used to reduce bleeding in mortality risk situations such as trauma." | 2.52 | Efficiency of tranexamic acid in perioperative blood loss in hip arthroplasty: a systematic literature review and meta-analysis. ( Díaz Quijano, DM; Pinzón-Florez, CE; Vélez Cañas, KM, 2015) |
| " As aetiology of haemoptysis as well as length of treatment, dosage and form of TA administration varied between the studies, strong recommendations are difficult to give." | 2.49 | Does tranexamic acid stop haemoptysis? ( Burrell, A; Dunning, J; Moen, CA, 2013) |
| "A standardized preoperative 2 g bolus TXA dosing regimen was associated with an excellent safety profile, and despite increased case complexity in terms of number of operative levels and operative time, patients treated with TXA did not require more blood transfusions than patients not treated with TXA." | 1.91 | Examining the safety profile of a standard dose tranexamic acid regimen in spine surgery. ( Adida, S; Dalton, J; Fourman, MS; Lee, JY; Mirvish, A; Sadhwani, S; Setliff, J; Shaw, JD; Tang, MY; Wawrose, R, 2023) |
| "Tranexamic acid is an effective treatment to reduce blood loss." | 1.91 | The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan. ( Chen, JW; Hou, SM; Hsu, HW; Hsu, LI; Wei, ST, 2023) |
| "Tranexamic acid (TXA) has shown to significantly reduce perioperative blood loss in elective orthopedic joint replacement surgery but is yet not implemented in acute hip fracture surgery for elderly patients who are particularly vulnerable to perioperative blood loss and postoperative anemia." | 1.72 | Clinical outcomes of tranexamic acid in acute hip hemiarthroplasties in frail geriatric patients. ( de Jong, L; Kuijper, TM; Roukema, GR; van Rijckevorsel, VAJIM, 2022) |
| " Thus, we conclude that it is safe to use TXA in this patient group." | 1.62 | Is tranexamic acid use in patients with a hip fracture safe? ( Andersen, LR; Clemmensen, SB; Gundtoft, PH; Halekoh, U; Lauritsen, J; Madsen, CF; Overgaard, S; Pedersen, L; Schønnemann, JO; Titlestad, K; Viberg, B, 2021) |
| "Tranexamic acid (TXA) has been shown to reduce blood loss and postoperative transfusions in total knee arthroplasty (TKA)." | 1.62 | One Versus Two Doses of Intravenous Tranexamic Acid in Total Knee Arthroplasty. ( Bernstein, JA; Charette, RS; Kamath, AF; Nchako, CM; Nelson, CL; Sloan, M, 2021) |
| "0, was employed to analyze demographics including surgical traits, blood loss, drainage, length of hospital stays (LOS), blood biochemical indices, prethrombotic state molecular markers, coagulation function, and adverse events." | 1.62 | Safety and Efficacy of Topical Administration of Tranexamic Acid in High-Risk Patients Undergoing Posterior Lumbar Interbody Fusion Surgery. ( Cai, T; Chen, D; Feng, X; Shi, P; Wang, J; Wang, S; Wang, Y; Zhang, L; Zhang, W, 2021) |
| "The intravenous TXA would reduce postoperative blood loss and transfusion requirements without increasing thromboembolic complications in open-wedge HTO." | 1.48 | Tranexamic acid is effective for blood management in open-wedge high tibial osteotomy. ( Bae, SH; Kim, GB; Kim, HJ; Kim, KI, 2018) |
| "For the TXA+ group, 0." | 1.46 | Low Risk of Thromboembolic Events After Routine Administration of Tranexamic Acid in Hip and Knee Arthroplasty. ( Husted, H; Kallemose, T; Madsen, RV; Nielsen, CS; Troelsen, A, 2017) |
| "Tranexamic acid was introduced during these procedures in 2006." | 1.43 | Use of Tranexamic Acid Is Associated with Reduced Blood Product Transfusion in Complex Skull Base Neurosurgical Procedures: A Retrospective Cohort Study. ( Akagami, R; Flexman, AM; Mebel, D, 2016) |
| "Tranexamic acid (TXA) is an antifibrinolytic that reduces blood loss after THA and TKA." | 1.43 | Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid. ( Campbell, JC; Mirocha, JM; Sharfman, ZT; Spitzer, AI, 2016) |
| "There were no deep venous thrombosis or thromboembolic complications in any group." | 1.43 | A comparative, retrospective study of peri-articular and intra-articular injection of tranexamic acid for the management of postoperative blood loss after total knee arthroplasty. ( Dai, K; Mao, Z; Wang, Y; Yan, M; Yue, B, 2016) |
| " We conclude that the intraarticular administration of TXA may be a safe and effective alternative for patients who have contraindications against intravenous TXA." | 1.43 | Intraarticular Administration of Tranexamic Acid is Safe and Effective in Total Knee Arthroplasty Patients at High-Risk for Thromboembolism. ( Chughtai, M; Delanois, RE; Gwam, C; Khlopas, A; Mistry, JB; Mont, MA; Mudaliar, PP; Tangri, V; Thomas, M, 2016) |
| "Tranexamic acid (TXA) has been used to reduce blood loss during total hip arthroplasty (THA), but its use could increase the risk of venous thromboembolic disease (VTE)." | 1.42 | Does tranexamic acid alter the risk of thromboembolism after total hip arthroplasty in the absence of routine chemical thromboprophylaxis? ( Hamada, M; Nishihara, S, 2015) |
| "Although TXA seemed safe and effective in this database review of patients with severe medical comorbidities, a larger prospective trial is warranted to confirm these results." | 1.40 | Preliminary results suggest tranexamic acid is safe and effective in arthroplasty patients with severe comorbidities. ( Duncan, C; Gillette, BP; Pagnano, MW; Sierra, RJ; Smith, H; Whiting, DR, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (4.27) | 18.7374 |
| 1990's | 3 (2.56) | 18.2507 |
| 2000's | 12 (10.26) | 29.6817 |
| 2010's | 54 (46.15) | 24.3611 |
| 2020's | 43 (36.75) | 2.80 |
| Authors | Studies |
|---|---|
| Sentilhes, L | 3 |
| Mattuizzi, A | 1 |
| Deneux-Tharaux, C | 2 |
| Taeuber, I | 1 |
| Choorapoikayil, S | 1 |
| Meybohm, P | 1 |
| Liu, W | 1 |
| Deng, S | 1 |
| Liang, J | 1 |
| Hourlier, H | 1 |
| Fennema, P | 1 |
| Albanese, R | 1 |
| Zingaretti, N | 1 |
| Almesberger, D | 1 |
| Parodi, PC | 1 |
| van Rijckevorsel, VAJIM | 1 |
| Roukema, GR | 1 |
| Kuijper, TM | 1 |
| de Jong, L | 1 |
| Karl, V | 1 |
| Thorn, S | 1 |
| Mathes, T | 1 |
| Hess, S | 1 |
| Maegele, M | 1 |
| Kornelsen, E | 1 |
| Kuppermann, N | 1 |
| Nishijima, DK | 1 |
| Ren, LY | 1 |
| Rumantir, M | 1 |
| Gill, PJ | 1 |
| Finkelstein, Y | 1 |
| Bierke, S | 1 |
| Häner, M | 1 |
| Bentzin, M | 1 |
| Park, HU | 1 |
| Petersen, W | 1 |
| Leverett, GD | 1 |
| Marriott, A | 1 |
| Spinella, PC | 1 |
| Bochicchio, K | 1 |
| Thomas, KA | 1 |
| Staudt, A | 1 |
| Shea, SM | 1 |
| Pusateri, AE | 1 |
| Schuerer, D | 1 |
| Levy, JH | 1 |
| Cap, AP | 1 |
| Bochicchio, G | 1 |
| Cornell, C | 1 |
| Miangul, S | 1 |
| Oluwaremi, T | 1 |
| El Haddad, J | 1 |
| Adra, M | 1 |
| Pinnawala, N | 1 |
| Nakanishi, H | 1 |
| Matar, RH | 1 |
| Than, CA | 1 |
| Stewart, TM | 1 |
| Hsu, LI | 3 |
| Hsu, HW | 3 |
| Chen, JW | 3 |
| Wei, ST | 3 |
| Hou, SM | 3 |
| Liechti, R | 1 |
| van de Wall, BJM | 1 |
| Hug, U | 1 |
| Fritsche, E | 1 |
| Franchi, A | 1 |
| White, K | 1 |
| Gagnon, Z | 1 |
| Cocchio, C | 1 |
| Tsan, SEH | 1 |
| Viknaswaran, NL | 1 |
| Cheong, CC | 1 |
| Cheah, S | 1 |
| Ng, KT | 1 |
| Mong, SXY | 1 |
| Wang, CY | 1 |
| Lin, YH | 1 |
| Lee, KC | 1 |
| Hsu, CC | 1 |
| Chen, KT | 1 |
| Polymeris, AA | 1 |
| Karwacki, GM | 1 |
| Siepen, BM | 1 |
| Schaedelin, S | 1 |
| Tsakiris, DA | 1 |
| Stippich, C | 1 |
| Guzman, R | 1 |
| Nickel, CH | 1 |
| Sprigg, N | 1 |
| Kägi, G | 1 |
| Vehoff, J | 1 |
| Barinka, F | 1 |
| Thilemann, S | 1 |
| Maurer, M | 1 |
| Wagner, B | 1 |
| Traenka, C | 1 |
| Gensicke, H | 1 |
| De Marchis, GM | 1 |
| Bonati, LH | 1 |
| Fischer, U | 1 |
| Z'Graggen, WJ | 1 |
| Nedeltchev, K | 1 |
| Wegener, S | 1 |
| Baumgartner, P | 1 |
| Engelter, ST | 1 |
| Seiffge, DJ | 1 |
| Peters, N | 1 |
| Lyrer, PA | 1 |
| Zhang, J | 2 |
| Fan, X | 1 |
| Zheng, Y | 1 |
| Wu, J | 1 |
| Yuan, X | 2 |
| Setliff, J | 1 |
| Dalton, J | 1 |
| Sadhwani, S | 1 |
| Tang, MY | 1 |
| Mirvish, A | 1 |
| Adida, S | 1 |
| Wawrose, R | 1 |
| Lee, JY | 1 |
| Fourman, MS | 1 |
| Shaw, JD | 1 |
| Izima, C | 1 |
| Sampath, SG | 1 |
| Tang, AJ | 1 |
| Ambati, VS | 1 |
| Chou, D | 1 |
| Chan, AK | 1 |
| Monaco, F | 1 |
| Nardelli, P | 1 |
| Pasin, L | 1 |
| Barucco, G | 1 |
| Mattioli, C | 1 |
| Di Tomasso, N | 1 |
| Dalessandro, G | 1 |
| Giardina, G | 1 |
| Landoni, G | 1 |
| Chiesa, R | 1 |
| Zangrillo, A | 1 |
| Ockerman, A | 1 |
| Vanhaverbeke, M | 1 |
| Miclotte, I | 1 |
| Belmans, A | 1 |
| Vanassche, T | 1 |
| Politis, C | 1 |
| Jacobs, R | 1 |
| Verhamme, P | 1 |
| Ackerman, RS | 1 |
| Hirschi, M | 1 |
| Trona, N | 1 |
| Joyce, DM | 1 |
| Evans, T | 1 |
| Patel, SY | 1 |
| Charette, RS | 1 |
| Bernstein, JA | 1 |
| Sloan, M | 1 |
| Nchako, CM | 1 |
| Kamath, AF | 1 |
| Nelson, CL | 1 |
| Morales Santias, M | 1 |
| Mas Martinez, J | 1 |
| Sanz-Reig, J | 1 |
| Martínez Gimenez, E | 1 |
| Verdu Román, C | 1 |
| Bustamante Suarez de Puga, D | 1 |
| Erramouspe, PJ | 1 |
| García-Pintos, MF | 1 |
| Benipal, S | 1 |
| Manoukian, MAC | 1 |
| Santamarina, JL | 1 |
| Shawagga, HG | 1 |
| Vo, LL | 1 |
| Galante, JM | 1 |
| Nishijima, D | 1 |
| Franchini, M | 1 |
| Mannucci, PM | 1 |
| Benhamou, D | 1 |
| Keita, H | 1 |
| Ducloy-Bouthors, AS | 1 |
| Perner, A | 1 |
| Møller, MH | 1 |
| Wirtz, MR | 1 |
| Schalkers, DV | 1 |
| Goslings, JC | 1 |
| Juffermans, NP | 1 |
| Weissler, JM | 1 |
| Banuelos, J | 1 |
| Jacobson, SR | 1 |
| Manrique, OJ | 1 |
| Nguyen, MT | 1 |
| Harless, CA | 1 |
| Tran, NV | 1 |
| Martinez-Jorge, J | 1 |
| Myckatyn, TM | 1 |
| Tenenbaum, MM | 1 |
| Ashkenazi, I | 1 |
| Schermann, H | 1 |
| Gold, A | 1 |
| Gurel, R | 1 |
| Chechik, O | 1 |
| Warschawski, Y | 1 |
| Schwarzkopf, R | 1 |
| Snir, N | 1 |
| Horton, LC | 1 |
| Feuerstein, JD | 1 |
| Shrestha, IK | 1 |
| Ruan, TY | 1 |
| Lin, L | 1 |
| Tan, M | 1 |
| Na, XQ | 1 |
| Qu, QC | 1 |
| Chen, JC | 1 |
| Si, YY | 1 |
| Tao, JP | 1 |
| Yen, SH | 1 |
| Lin, PC | 1 |
| Wu, CT | 1 |
| Wang, JW | 1 |
| Reale, D | 1 |
| Andriolo, L | 1 |
| Gursoy, S | 1 |
| Bozkurt, M | 1 |
| Filardo, G | 1 |
| Zaffagnini, S | 1 |
| Viberg, B | 1 |
| Gundtoft, PH | 1 |
| Schønnemann, JO | 1 |
| Pedersen, L | 1 |
| Andersen, LR | 1 |
| Titlestad, K | 1 |
| Madsen, CF | 1 |
| Clemmensen, SB | 1 |
| Halekoh, U | 1 |
| Lauritsen, J | 1 |
| Overgaard, S | 1 |
| Shi, P | 1 |
| Wang, J | 3 |
| Cai, T | 1 |
| Chen, D | 1 |
| Wang, S | 1 |
| Feng, X | 1 |
| Wang, Y | 3 |
| Zhang, W | 1 |
| Zhang, L | 1 |
| Rampotas, A | 1 |
| Watson, E | 1 |
| Burton, K | 1 |
| Hill, QA | 1 |
| Pavord, S | 1 |
| Mi, B | 1 |
| Liu, G | 1 |
| Lv, H | 1 |
| Liu, Y | 1 |
| Zha, K | 1 |
| Wu, Q | 1 |
| Liu, J | 1 |
| Jansen, JA | 1 |
| Lameijer, JRC | 1 |
| Snoeker, BAM | 1 |
| Dai, WL | 1 |
| Zhou, AG | 1 |
| Zhang, H | 1 |
| Wang, Q | 1 |
| Zhang, X | 1 |
| Fillingham, YA | 1 |
| Ramkumar, DB | 1 |
| Jevsevar, DS | 1 |
| Yates, AJ | 1 |
| Shores, P | 1 |
| Mullen, K | 1 |
| Bini, SA | 1 |
| Clarke, HD | 1 |
| Schemitsch, E | 1 |
| Johnson, RL | 1 |
| Memtsoudis, SG | 1 |
| Sayeed, SA | 1 |
| Sah, AP | 1 |
| Della Valle, CJ | 1 |
| Guo, P | 1 |
| He, Z | 1 |
| Gao, F | 2 |
| Sun, W | 2 |
| Guo, W | 2 |
| Li, Z | 2 |
| Cheng, L | 2 |
| Longo, MA | 1 |
| Cavalheiro, BT | 1 |
| de Oliveira Filho, GR | 1 |
| White, CC | 1 |
| Eichinger, JK | 1 |
| Friedman, RJ | 1 |
| Chakroun-Walha, O | 1 |
| Samet, A | 1 |
| Jerbi, M | 1 |
| Nasri, A | 1 |
| Talbi, A | 1 |
| Kanoun, H | 1 |
| Souissi, B | 1 |
| Chtara, K | 1 |
| Bouaziz, M | 1 |
| Ksibi, H | 1 |
| Rekik, N | 1 |
| Zhu, Q | 1 |
| Yu, C | 1 |
| Chen, X | 1 |
| Xu, X | 1 |
| Chen, Y | 1 |
| Liu, C | 1 |
| Lin, P | 1 |
| Palanisamy, JV | 1 |
| Das, S | 1 |
| Moon, KH | 1 |
| Kim, DH | 2 |
| Kim, TK | 1 |
| Winer, N | 1 |
| Azria, E | 1 |
| Sénat, MV | 1 |
| Le Ray, C | 1 |
| Vardon, D | 1 |
| Perrotin, F | 1 |
| Desbrière, R | 1 |
| Fuchs, F | 1 |
| Kayem, G | 1 |
| Ducarme, G | 1 |
| Doret-Dion, M | 1 |
| Huissoud, C | 1 |
| Bohec, C | 1 |
| Deruelle, P | 1 |
| Darsonval, A | 1 |
| Chrétien, JM | 1 |
| Seco, A | 1 |
| Daniel, V | 1 |
| Maeda, T | 1 |
| Michihata, N | 1 |
| Sasabuchi, Y | 1 |
| Matsui, H | 1 |
| Ohnishi, Y | 1 |
| Miyata, S | 1 |
| Yasunaga, H | 1 |
| Zhang, P | 1 |
| Bai, J | 1 |
| He, J | 1 |
| Liang, Y | 1 |
| Chen, P | 1 |
| Kim, KI | 1 |
| Kim, HJ | 1 |
| Kim, GB | 1 |
| Bae, SH | 1 |
| Huerfano, E | 1 |
| Huerfano, M | 1 |
| Shanaghan, KA | 1 |
| Gonzalez Della Valle, A | 1 |
| Yates, J | 1 |
| Perelman, I | 1 |
| Khair, S | 1 |
| Taylor, J | 1 |
| Lampron, J | 1 |
| Tinmouth, A | 1 |
| Saidenberg, E | 1 |
| Reichel, F | 1 |
| Peter, C | 1 |
| Ewerbeck, V | 1 |
| Egermann, M | 1 |
| Kim, S | 1 |
| Kang, H | 1 |
| Jin, HJ | 1 |
| Hwang, SH | 1 |
| Wang, D | 1 |
| Yang, Y | 1 |
| He, C | 1 |
| Luo, ZY | 1 |
| Pei, FX | 1 |
| Li, Q | 1 |
| Zhou, ZK | 1 |
| Zeng, WN | 1 |
| Dibiasi, C | 1 |
| Wiegele, M | 2 |
| Gratz, J | 1 |
| Schöchl, H | 1 |
| Haushofer, A | 1 |
| Ortler, M | 1 |
| Leitgeb, J | 1 |
| Kwasny, O | 1 |
| Beer, R | 1 |
| Ay, C | 1 |
| Schaden, E | 1 |
| Zhang, S | 1 |
| Wang, C | 1 |
| Shi, L | 1 |
| Xue, Q | 1 |
| Tille, E | 1 |
| Mysliwietz, J | 1 |
| Beyer, F | 1 |
| Postler, A | 1 |
| Lützner, J | 1 |
| Tammachote, N | 1 |
| Raphiphan, R | 1 |
| Kanitnate, S | 1 |
| Whiting, DR | 1 |
| Gillette, BP | 2 |
| Duncan, C | 1 |
| Smith, H | 1 |
| Pagnano, MW | 2 |
| Sierra, RJ | 2 |
| Guerrero-Domínguez, R | 1 |
| Padilla-Morales, V | 1 |
| Montero-López, N | 1 |
| Marenco de la Fuente, ML | 1 |
| Moen, CA | 1 |
| Burrell, A | 1 |
| Dunning, J | 1 |
| Linkins, LA | 1 |
| Moffat, K | 1 |
| Wang, H | 1 |
| Shen, B | 1 |
| Zeng, Y | 1 |
| Pinzón-Florez, CE | 1 |
| Vélez Cañas, KM | 1 |
| Díaz Quijano, DM | 1 |
| Wang, W | 1 |
| Nishihara, S | 1 |
| Hamada, M | 1 |
| Bouet, PE | 1 |
| Ruiz, V | 1 |
| Legendre, G | 1 |
| Gillard, P | 1 |
| Descamps, P | 1 |
| Jain, NP | 1 |
| Nisthane, PP | 1 |
| Shah, NA | 1 |
| Mebel, D | 1 |
| Akagami, R | 1 |
| Flexman, AM | 1 |
| Sharfman, ZT | 1 |
| Campbell, JC | 1 |
| Mirocha, JM | 1 |
| Spitzer, AI | 1 |
| Kietpeerakool, C | 1 |
| Supoken, A | 1 |
| Laopaiboon, M | 1 |
| Lumbiganon, P | 1 |
| Estcourt, LJ | 1 |
| Desborough, M | 1 |
| Brunskill, SJ | 1 |
| Doree, C | 1 |
| Hopewell, S | 1 |
| Murphy, MF | 1 |
| Stanworth, SJ | 1 |
| Jessing, TD | 1 |
| Fenger-Eriksen, C | 1 |
| Nielsen, CS | 2 |
| Jans, Ø | 1 |
| Ørsnes, T | 1 |
| Foss, NB | 1 |
| Troelsen, A | 2 |
| Husted, H | 2 |
| Soroceanu, A | 1 |
| Oren, JH | 1 |
| Smith, JS | 1 |
| Hostin, R | 1 |
| Shaffrey, CI | 1 |
| Mundis, GM | 1 |
| Ames, CP | 1 |
| Burton, DC | 1 |
| Bess, S | 1 |
| Gupta, MC | 1 |
| Deviren, V | 1 |
| Schwab, FJ | 1 |
| Lafage, V | 1 |
| Errico, TJ | 1 |
| Pinsornsak, P | 1 |
| Rojanavijitkul, S | 1 |
| Chumchuen, S | 1 |
| Kim, YH | 1 |
| Park, JW | 1 |
| Kim, JS | 1 |
| Queiroz, SI | 1 |
| Alves, HS | 1 |
| de Assis, GM | 1 |
| Conceicao, TS | 1 |
| Germano, AR | 1 |
| da Silva, JS | 1 |
| Mao, Z | 1 |
| Yue, B | 1 |
| Yan, M | 1 |
| Dai, K | 1 |
| Madsen, RV | 1 |
| Kallemose, T | 1 |
| Delanois, RE | 1 |
| Gwam, C | 1 |
| Mistry, JB | 1 |
| Chughtai, M | 1 |
| Thomas, M | 1 |
| Mudaliar, PP | 1 |
| Khlopas, A | 1 |
| Tangri, V | 1 |
| Mont, MA | 1 |
| Badenoch, A | 1 |
| Sharma, A | 1 |
| Gower, S | 1 |
| Selzner, M | 1 |
| Srinivas, C | 1 |
| Wąsowicz, M | 1 |
| McCluskey, SA | 1 |
| Madrid, C | 1 |
| Sanz, M | 1 |
| Adler Ma, SC | 1 |
| Brindle, W | 1 |
| Burton, G | 1 |
| Gallacher, S | 1 |
| Hong, FC | 1 |
| Manelius, I | 1 |
| Smith, A | 1 |
| Ho, W | 1 |
| Alston, RP | 1 |
| Bhattacharya, K | 1 |
| Ker, K | 1 |
| Edwards, P | 1 |
| Perel, P | 1 |
| Shakur, H | 1 |
| Roberts, I | 1 |
| Loomba, A | 1 |
| Loomba, K | 1 |
| Bains, R | 1 |
| Bains, VK | 1 |
| DeSimone, LJ | 1 |
| Trousdale, RT | 1 |
| Chow, KM | 1 |
| Szeto, CC | 1 |
| Dalmau, A | 1 |
| Sabaté, A | 1 |
| Koo, M | 1 |
| Bartolomé, C | 1 |
| Rafecas, A | 1 |
| Figueras, J | 1 |
| Jaurrieta, E | 1 |
| Xia, VW | 1 |
| Steadman, RH | 1 |
| Sacco, R | 1 |
| Sacco, M | 1 |
| Carpenedo, M | 1 |
| Moia, M | 1 |
| Groenland, TH | 1 |
| Porte, RJ | 2 |
| Molenaar, IQ | 1 |
| Warnaar, N | 1 |
| Groen, H | 1 |
| Tenvergert, EM | 1 |
| Slooff, MJ | 1 |
| Myles, P | 1 |
| Lozano, M | 1 |
| Basora, M | 1 |
| Peidro, L | 1 |
| Merino, I | 1 |
| Segur, JM | 1 |
| Pereira, A | 1 |
| Salazar, F | 1 |
| Cid, J | 1 |
| Lozano, L | 1 |
| Mazzara, R | 1 |
| Macule, F | 1 |
| Smart, CJ | 1 |
| Lindoff, C | 1 |
| Rybo, G | 1 |
| Astedt, B | 1 |
| Souto, JC | 1 |
| Oliver, A | 1 |
| Zuazu-Jausoro, I | 1 |
| Vives, A | 1 |
| Fontcuberta, J | 1 |
| Howes, JP | 1 |
| Sharma, V | 1 |
| Cohen, AT | 1 |
| Webster, K | 1 |
| Wilde, J | 1 |
| Gruber, EM | 1 |
| Shukla, AC | 1 |
| Reid, RW | 1 |
| Hickey, PR | 1 |
| Hansen, DD | 1 |
| Zohar, E | 1 |
| Fredman, B | 1 |
| Ellis, MH | 1 |
| Ifrach, N | 1 |
| Stern, A | 1 |
| Jedeikin, R | 1 |
| Engqvist, A | 1 |
| Broström, O | 1 |
| von Feilitzen, F | 1 |
| Halldin, M | 1 |
| Nyström, B | 1 |
| Ost, A | 1 |
| Reichard, H | 1 |
| Sandqvist, S | 1 |
| Törngren, S | 1 |
| Wedlund, JE | 1 |
| Carlin, G | 1 |
| Modig, J | 1 |
| Saldeen, T | 1 |
| Prentice, CR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma[NCT05713630] | Phase 3 | 130 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| Tranexamic Acid in Major Vascular Surgery. A Randomized Placebo-controlled Trial.[NCT02335359] | Phase 4 | 100 participants (Actual) | Interventional | 2015-03-04 | Completed | ||
| Efficacy of Local Hemostatic Management in Implant Surgery in Anticoagulated Patients on Warfarin: a Randomized Clinical Study[NCT04846114] | 71 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Precise Application of Topical Tranexamic Acid to Enhance Endoscopic Hemostasis for Peptic Ulcer Bleeding: A Randomized Controlled Study[NCT05248321] | 60 participants (Actual) | Interventional | 2022-03-24 | Completed | |||
| Tranexamic Acid for the Treatment of Gastrointestinal Haemorrhage: an International Randomised, Double Blind Placebo Controlled Trial[NCT01658124] | Phase 3 | 12,009 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| Use of TRanEXamic Acid in Reduction Mammoplasty (TREX-ARM): a Double-blinded Randomized Controlled Trial[NCT04947514] | Phase 4 | 98 participants (Actual) | Interventional | 2021-10-29 | Completed | ||
| Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage[NCT05554211] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-07-12 | Recruiting | ||
| Comparison of Topical Tranexamic Acid and Floseal® on Blood Loss After Total Knee Arthroplasty in Patients With a Thromboembolic Risk[NCT02865174] | Phase 4 | 90 participants (Anticipated) | Interventional | 2016-09-30 | Not yet recruiting | ||
| Extended Postoperative Tranexamic Acid Use in Primary Total Knee Arthroplasty: A Prospective, Randomized Controlled Trial[NCT05099276] | Phase 4 | 46 participants (Actual) | Interventional | 2021-12-07 | Active, not recruiting | ||
| Evaluation of Tranexamic Acid Prior to Surgery in the Geriatric Hip Fracture Population for the Reduction of Post-Operative Blood Transfusion[NCT03923959] | Phase 3 | 400 participants (Anticipated) | Interventional | 2020-02-01 | Active, not recruiting | ||
| Comparative Use of Tranexamic Acid Intravenous and Topical Application in the Treatment of Intertrochanteric Fractures With Proximate Femoral Nail[NCT04696224] | 90 participants (Anticipated) | Interventional | 2020-12-18 | Recruiting | |||
| Effect of no Drainage Tube on Blood Loss and Recovery After High Tibial Osteotomy[NCT03954860] | 80 participants (Actual) | Interventional | 2018-08-01 | Completed | |||
| Evaluation of the Use of Tranexamic Acid in Tibial Osteotomies: a Randomised Controlled Clinical Trial.[NCT04785651] | 84 participants (Anticipated) | Interventional | 2021-02-22 | Recruiting | |||
| Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery: a Multicenter Randomised Double Blind Placebo Controlled Trial[NCT02302456] | Phase 3 | 4,079 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Use of Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery[NCT03856164] | Phase 2/Phase 3 | 110 participants (Actual) | Interventional | 2019-06-17 | Completed | ||
| Efficacy of Tranexamic Acid in Reducing Requirement of Blood Transfusion in Lower Limb Trauma Surgery: A Prospective Randomized Controlled Study[NCT04986813] | Phase 4 | 100 participants (Actual) | Interventional | 2017-04-01 | Completed | ||
| Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery[NCT04754230] | Phase 4 | 40 participants (Actual) | Interventional | 2021-06-17 | Completed | ||
| Efficacy of Postoperative Pain Control Between Transarticular VS Periartiucular Multimodal Drug Infiltration in Total Hip Arthroplasty: Double-blinded Randomized Control Trial[NCT05325671] | 120 participants (Anticipated) | Interventional | 2022-04-05 | Not yet recruiting | |||
| [NCT02644473] | Phase 4 | 0 participants (Actual) | Interventional | 2016-02-29 | Withdrawn (stopped due to Study did not receive IRB approval, so did not start) | ||
| Postoperative Drainage in Total Knee Arthroplasty in the Presence of Tranexamic Acid: a Clinical Trial[NCT03915756] | 42 participants (Anticipated) | Interventional | 2019-08-22 | Recruiting | |||
| The Comparative Efficacy of Peri-articular and Intraarticular Tranexamic Acid in Total Knee Arthroplasty: A Prospective, Double-Blind Randomized, Controlled Trial[NCT03074994] | Phase 2 | 108 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | ||
| Topical Application of Tranexamic Acid to Reduce Postoperative Blood Loss in Posterior Approach Spinal Surgery[NCT02063035] | Phase 4 | 29 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Evaluation of Efficacy and Safety of Perioperative Tranexamic Acid During Primary Total Knee Arthroplasty: A Randomized, Clinical Trial[NCT05919615] | 100 participants (Actual) | Interventional | 2021-07-15 | Completed | |||
| A Randomized Control Trial Evaluating the Use of Topical Tranexamic Acid in Bilateral Breast Reduction Surgery to Prevent Bleeding Complications[NCT04918576] | Phase 3 | 106 participants (Anticipated) | Interventional | 2022-08-31 | Not yet recruiting | ||
| Serial Use of Intravenous and Oral Tranexamic Acid in Primary Total Knee Arthroplasty Patients: A Randomized Controlled Study[NCT03109652] | Phase 4 | 144 participants (Anticipated) | Interventional | 2017-07-10 | Recruiting | ||
| Effects of Tranexamic Acid for Alloplastic Breast Reconstruction: A Randomized Control Trial[NCT04918589] | Phase 3 | 106 participants (Anticipated) | Interventional | 2022-08-31 | Not yet recruiting | ||
| Comparison of Combined Topical Tranexamic Acid With Floseal® With Intravenous Tranexamic Acid on Blood Loss in Total Knee Arthroplasty[NCT03328832] | Phase 4 | 70 participants (Actual) | Interventional | 2017-09-12 | Completed | ||
| Prevention of Postpartum Hemorrhage With Tranexamic Acid (TXA)[NCT03326596] | Phase 4 | 1,000 participants (Anticipated) | Interventional | 2018-04-20 | Recruiting | ||
| Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery: A Double-Blind Randomized Controlled Trial[NCT04863339] | Phase 2 | 0 participants (Actual) | Interventional | 2022-03-31 | Withdrawn (stopped due to Challenges in recruitment) | ||
| Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer[NCT04360629] | 151 participants (Actual) | Interventional | 2020-06-03 | Completed | |||
| Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty: A Randomized Controlled Trial[NCT02829346] | Phase 2 | 60 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Prospective Randomized Study Comparing Topical Versus Intravenous Tranexamic Acid in Anterior Total Hip Arthroplasty[NCT03359525] | Phase 4 | 114 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | ||
| Prophylactic Use of Topical Tranexamic Acid to Aid Surgical Haemostasis During Caesarean Sections in Parturients With Moderate to High Risk of Bleeding[NCT02492087] | Phase 3 | 84 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| Prophylactic Use of Tranexamic Acid for Preventing Postpartum Hemorrhage: A Randomized, Double-blinded, Placebo-controlled Pilot Trial[NCT03069859] | Phase 2 | 31 participants (Actual) | Interventional | 2018-03-06 | Active, not recruiting | ||
| IV Tranexamic Acid Prior to Hysterectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial[NCT02911831] | Early Phase 1 | 71 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty[NCT03825939] | Phase 4 | 52 participants (Actual) | Interventional | 2015-04-21 | Terminated (stopped due to Lack of patient enrollment due to only one surgeon that was enrolling.) | ||
| A Randomized Comparison of Two Doses of Tranexamic Acid in Open-Heart Surgery[NCT04996368] | 120 participants (Actual) | Interventional | 2022-02-01 | Completed | |||
| The Effect of Tranexamic Acid (TXA) on Blood Loss in Burn Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial[NCT03113253] | Phase 4 | 121 participants (Actual) | Interventional | 2016-09-22 | Active, not recruiting | ||
| Minimization of Bleeding Complications Through Utilization of Perioperative Tranexamic Acid in Breast Surgery: A Randomized Double-blinded Placebo-controlled Trial[NCT02615366] | Phase 4 | 800 participants (Anticipated) | Interventional | 2016-02-29 | Not yet recruiting | ||
| The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
| Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study[NCT00740116] | Phase 4 | 100 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of breasts with clinically significant hematoma (collection of blood under the skin) requiring either conservative management or operative washout was determined. (NCT04947514)
Timeframe: Up to 30 days
| Intervention | breasts (Number) |
|---|---|
| Treatment Side (Right or Left) | 2 |
| Placebo Side (Right or Left) | 1 |
The number of participants requiring blood transfusion was based on the postoperative decline in hematocrit level (NCT04947514)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Side (Right or Left) | 0 |
| Placebo Side (Right or Left) | 0 |
Incidence of clinically significant deep vein thrombosis or pulmonary embolism detected on imaging (ultrasound or CT scan) (NCT04947514)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Side (Right or Left) | 0 |
| Placebo Side (Right or Left) | 0 |
Total blood volume loss will be calculated in milliliters. (NCT03856164)
Timeframe: 24 hours postpartum.
| Intervention | milliliters (Mean) |
|---|---|
| Tranexamic Acid | 2274 |
| Placebo | 2407 |
Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | µg/mL (Mean) | ||
|---|---|---|---|
| Before Surgery | After Delivery | P.O.D. 1 | |
| Placebo | 4.0 | 3.8 | 4.3 |
| Tranexamic Acid | 2.9 | 2.4 | 2.1 |
Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Before Surgery | After Delivery | P.O.D. 1 | |
| Placebo | 550.7 | 484.9 | 525.4 |
| Tranexamic Acid | 563.5 | 499.6 | 527.4 |
Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | IU/mL (Mean) | ||
|---|---|---|---|
| Before Surgery | After Delivery | P.O.D. 1 | |
| Placebo | 61.7 | 63.3 | 22.1 |
| Tranexamic Acid | 81.8 | 67.0 | 20.7 |
Rotational thromboelastometry is a whole blood viscoelastic test that analyzes deficits in clotting factors, clot strength, and clot breakdown. EXTEM, INTEM, and FIBTEM tests measure the extrinsic pathway, intrinsic pathway, and fibrinogen levels, respectively. Compared to non-pregnant patients, FIBTEM/EXTEM/INTEM amplitudes and the FIBTEM maximum clot firmness are higher in pregnant women. The EXTEM and INTEM clotting time are shorter, indicating the relative hypercoagulability of pregnancy. Reference ranges for INTEM Clotting Time (100-240 seconds), INTEM Maximum Clot Firmness (50-72 millimeter), EXTEM Clotting Time (38-79 seconds), EXTEM Maximum Clot Firmness (50-72 millimeter), FIBTEM Maximum Clot Firmness (9-25 millimeter). (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | seconds (Mean) | |||||
|---|---|---|---|---|---|---|
| Before Surgery INTEM Clotting Time | After Delivery INTEM Clotting Time | P.O.D. 1 INTEM Clotting Time | Before Surgery EXTEM Clotting Time | After Delivery EXTEM Clotting Time | P.O.D. 1 EXTEM Clotting Time | |
| Placebo | 150.5 | 140.7 | 141.2 | 56.1 | 56.3 | 50.2 |
| Tranexamic Acid | 149.7 | 137.4 | 145.1 | 54.0 | 54.9 | 49.3 |
Rotational thromboelastometry is a whole blood viscoelastic test that analyzes deficits in clotting factors, clot strength, and clot breakdown. EXTEM, INTEM, and FIBTEM tests measure the extrinsic pathway, intrinsic pathway, and fibrinogen levels, respectively. Compared to non-pregnant patients, FIBTEM/EXTEM/INTEM amplitudes and the FIBTEM maximum clot firmness are higher in pregnant women. The EXTEM and INTEM clotting time are shorter, indicating the relative hypercoagulability of pregnancy. Reference ranges for INTEM Clotting Time (100-240 seconds), INTEM Maximum Clot Firmness (50-72 millimeter), EXTEM Clotting Time (38-79 seconds), EXTEM Maximum Clot Firmness (50-72 millimeter), FIBTEM Maximum Clot Firmness (9-25 millimeter). (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | millimeter (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Before Surgery INTEM Maximum Clot Firmness | After Delivery INTEM Maximum Clot Firmness | P.O.D. 1 INTEM Maximum Clot Firmness | Before Surgery EXTEM Maximum Clot Firmness | After Delivery EXTEM Maximum Clot Firmness | P.O.D. 1 EXTEM Maximum Clot Firmness | Before Surgery FIBTEM Maximum Clot Firmness | After Delivery FIBTEM Maximum Clot Firmness | P.O.D. 1 FIBTEM Maximum Clot Firmness | |
| Placebo | 69.4 | 68.4 | 68.8 | 71.2 | 69.6 | 70.4 | 23.9 | 22.0 | 25.0 |
| Tranexamic Acid | 69.3 | 68.9 | 68.8 | 70.8 | 69.8 | 70.5 | 24.2 | 22.5 | 25.8 |
Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | ng/mL (Mean) | ||
|---|---|---|---|
| Before Surgery | After Delivery | P.O.D. 1 | |
| Placebo | 8.2 | 9.6 | 7.4 |
| Tranexamic Acid | 8.1 | 9.0 | 7.5 |
Patient-reported Visual Analog Scale - Bleeding Score Day 1. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 1 (assessed within first 24 hours following surgery)
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 5.03 |
| 1,000mg IV Tranexamic Acid | 4.82 |
Patient-reported Visual Analog Scale - Bleeding Score Day 2. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 2
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 4.47 |
| 1,000mg IV Tranexamic Acid | 3.89 |
Patient-reported Visual Analog Scale - Bleeding Score Day 3. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 3
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 2.93 |
| 1,000mg IV Tranexamic Acid | 2.29 |
Patient-reported Visual Analog Scale - Bleeding Score Day 4. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 4
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 2.12 |
| 1,000mg IV Tranexamic Acid | 1.44 |
Patient-reported Visual Analog Scale - Bleeding Score Day 5. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 5
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 1.32 |
| 1,000mg IV Tranexamic Acid | 1.15 |
Patient-reported Visual Analog Scale - Bleeding Score Day 6. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 6
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 1.36 |
| 1,000mg IV Tranexamic Acid | 0.76 |
Patient-reported Visual Analog Scale - Bleeding Score Day 7. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 7
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 0.97 |
| 1,000mg IV Tranexamic Acid | 0.72 |
Number of patients in each arm requiring evaluation by the resident service for bleeding concerns expressed by the recovery nurse (in PACU), had any follow-up visit or phone call outside of regularly scheduled follow-up (NCT04754230)
Timeframe: Day of surgery through 1 week
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| PACU | Follow-up visit | Follow-up phone call | |
| 1,000mg IV Tranexamic Acid | 0 | 1 | 2 |
| Normal Saline | 0 | 0 | 2 |
Patient-reported Visual Analog Scale - Guaze Saturation Score through Postoperative Day 7. Score range: 0 (not at all) to 10 (dripping blood). (NCT04754230)
Timeframe: Postoperative Day 2 through Postoperative Day 7
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Postoperative day 2 | Postoperative day 3 | Postoperative day 4 | Postoperative day 5 | Postoperative day 6 | Postoperative day 7 | |
| 1,000mg IV Tranexamic Acid | 4.56 | 2.09 | 0.76 | 0.40 | 0.29 | 0.28 |
| Normal Saline | 5.16 | 3.03 | 1.74 | 1.11 | 0.99 | 0.80 |
Blood loss following surgery was defined as the total amount of fluid collected from the drain in the wound site during the hospital stay. (NCT02063035)
Timeframe: From end of surgery on Day 1 to end of hospital stay up to approximately 5 days
| Intervention | mL (Median) |
|---|---|
| Tranexamic Acid | 534 |
| Placebo | 530 |
Blood loss was calculated from the difference between the level of hemoglobin at the preoperative appointment and the lowest level during the postoperative hospitalization period. Reported here is the change in hemoglobin level after surgery. A negative number indicates a reduction in hemoglobin level. (NCT02063035)
Timeframe: From preoperative appointment approximately one week before surgery to end of hospital stay up to approximately 5 days after surgery
| Intervention | grams per deciliter (g/dL) (Median) |
|---|---|
| Tranexamic Acid | -3.2 |
| Placebo | -4.6 |
The number of days the participants stayed in the hospital after surgery was recorded. (NCT02063035)
Timeframe: From end of surgery on Day 1 to end of hospital stay up to approximately 2 weeks
| Intervention | days (Median) |
|---|---|
| Tranexamic Acid | 5 |
| Placebo | 6 |
All units of blood transfused during the hospital stay after surgery were recorded. One red blood cell unit contains 300 to 360 mL of whole blood. (NCT02063035)
Timeframe: From end of surgery on Day 1 to end of hospital stay up to approximately 5 days
| Intervention | units of blood (Median) |
|---|---|
| Tranexamic Acid | 0 |
| Placebo | 0 |
We will record the event of blood transfusion, and calculate the incidence of transfusion (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Combined Topical TXA and Floseal | 1 |
| Topical TXA Alone | 0 |
The composite of any venous thromoembolism events, ischemic heart attacks, cerebrovascular accidents (NCT03328832)
Timeframe: within 30 days of the operation
| Intervention | Participants (Count of Participants) |
|---|---|
| Combined Topical TXA and Floseal | 0 |
| Topical TXA Alone | 0 |
Total blood loss was calculated according to Nadler et al., which used maximum postoperative reduction of the Hb level adjust for weight and height of the patient. The formula is as follows, Total blood loss = (Total blood volume x [change in Hb level / preoperative Hb level])x1000+volume transfused (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4
| Intervention | ml (Mean) |
|---|---|
| Combined Topical TXA and Floseal | 678 |
| Topical TXA Alone | 733 |
Measured in Days (NCT03825939)
Timeframe: At Hospital Discharge
| Intervention | Days (Mean) |
|---|---|
| Intravenous Tranexamic Acid | 3 |
| Intravenous Placebo | 3 |
| Intravenous Tranexamic Acid Followed by Intravenous Placebo | 3 |
Median number of red blood cells transfused among those who received RBC transfusions (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | units (Median) |
|---|---|
| The Placebo Group | 2 |
| The Tranexamic Acid Group | 2 |
Total number of RBC-transfused women in each group (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | participants (Number) |
|---|---|
| Tranexamic Group | 15 |
| Placebo Group | 22 |
Thromboembolic events including arterial thrombosis, muscle vein thrombosis, superficial and deep venous thrombosis. (NCT00740116)
Timeframe: From time of operation to 5 weeks postoperatively.
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Group | 2 |
| Placebo Group | 5 |
Total number of red blood cells (RBC) transfused across all participants (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | units (Number) |
|---|---|
| Tranexamic Group | 38 |
| Placebo Group | 53 |
Estimation of total blood loss was based on the estimation of the Hb balance method (Brecher, et al.1997) with the assumption that the body blood volume was normalised on the fifth postoperative day. The haemoglobin level was assessed preoperatively and on the fifth postoperative day. The predicted blood volume (PBV, l) was calculated according to the method described by Nadler et al. (1962), using body weight and height. The extravasation of haemoglobin was calculated taking into account allogenic transfused haemoglobin. Total blood loss perioperatively was related to the patient's preoperative haemoglobin value. Blood loss due to haematomas or a reoperation within the first five days after surgery was also considered. (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | milliliter (Median) |
|---|---|
| Tranexamic Group | 520 |
| Placebo Group | 730 |
42 reviews available for tranexamic acid and Thromboembolism
| Article | Year |
|---|---|
Tranexamic acid usage in hip fracture surgery: a meta-analysis and meta-regression analysis of current practice.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2022 |
Association of Tranexamic Acid Administration With Mortality and Thromboembolic Events in Patients With Traumatic Injury: A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Hemorrhage; Humans; Thromboembolism; Tranexamic | 2022 |
Effectiveness and safety of tranexamic acid in pediatric trauma: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Child; Humans; Retrospective Studies; Thromboembolism; Tranexamic Acid | 2022 |
The use of tranexamic acid reduces blood loss in osteotomy at knee level: a systematic review.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemoglobins; Humans; Osteotomy; Postoperative Hemorrh | 2022 |
Intravenous tranexamic acid and thromboembolic events in hip fracture surgery: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemoglobins; Hip Frac | 2023 |
Update on the efficacy and safety of intravenous tranexamic acid in hip fracture surgery: a systematic review and meta-analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Hip Fractures; Humans; P | 2023 |
Tranexamic Acid Use in Breast Surgery: A Systematic Review and Meta-Analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Breast Neoplasms; Female; Hematoma; Humans; Mastectom | 2023 |
Prophylactic intravenous tranexamic acid and thromboembolism in non-cardiac surgery: a systematic review, meta-analysis and trial sequential analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Thr | 2023 |
Efficacy and safety of intravenous tranexamic acid in urologic surgery: A systematic review and meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Randomized Controlled Trials as Topic; Thromb | 2023 |
Intravenous application of tranexamic acid in intramedullary nailing for the treatment of geriatric intertrochanteric fractures: a systematic review and meta-analysis.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Fracture Fixation, | 2023 |
Systematic review and meta-analysis of topical tranexamic acid in spine surgery.
Topics: Blood Loss, Surgical; Case-Control Studies; Cross-Sectional Studies; Hemoglobins; Humans; Postoperat | 2023 |
Incidence of Thromboembolic Events in Oncology Patients Receiving Intraoperative Tranexamic Acid During Orthopedic Surgery: A Retrospective Review at a Comprehensive Cancer Center.
Topics: Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Incidence; Intraoperativ | 2020 |
The never ending success story of tranexamic acid in acquired bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Thromboembolism; Tranexami | 2020 |
Coagulation changes and thromboembolic risk in COVID-19 obstetric patients.
Topics: Anticoagulants; Autoantibodies; Betacoronavirus; Blood Proteins; Cerebrovascular Disorders; Contrain | 2020 |
The impact of blood product ratio and procoagulant therapy on the development of thromboembolic events in severely injured hemorrhaging trauma patients.
Topics: Antifibrinolytic Agents; Blood Coagulation Factors; Blood Component Transfusion; Factor VIIa; Fibrin | 2020 |
The efficacy and safety of high-dose tranexamic acid in adolescent idiopathic scoliosis: a meta-analysis.
Topics: Adolescent; Blood Loss, Surgical; Female; Humans; Infusions, Intravenous; Intraoperative Complicatio | 2021 |
Complications of Tranexamic Acid in Orthopedic Lower Limb Surgery: A Meta-Analysis of Randomized Controlled Trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Humans; Lo | 2021 |
Is combined use of intravenous and intraarticular tranexamic acid superior to intravenous or intraarticular tranexamic acid alone in total knee arthroplasty? A meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2017 |
Most Effective Regimen of Tranexamic Acid for Reducing Bleeding and Transfusions in Primary Total Knee Arthroplasty: A Meta-Analysis of Randomized Controlled Trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2018 |
The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement; Blood Loss, Surgical; Humans; Thromboembolism; T | 2018 |
The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement; Blood Loss, Surgical; Humans; Thromboembolism; T | 2018 |
The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement; Blood Loss, Surgical; Humans; Thromboembolism; T | 2018 |
The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement; Blood Loss, Surgical; Humans; Thromboembolism; T | 2018 |
Efficacy and safety of oral tranexamic acid in total knee arthroplasty: A systematic review and meta-analysis.
Topics: Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical | 2018 |
Systematic review and meta-analyses of tranexamic acid use for bleeding reduction in prostate surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Incidence; Male; Prostatec | 2018 |
Efficacy and Safety of Tranexamic Acid for Blood Salvage in Intertrochanteric Fracture Surgery: A Meta-Analysis.
Topics: Hip Fractures; Humans; Operative Blood Salvage; Postoperative Complications; Thromboembolism; Tranex | 2018 |
A systematic review of tranexamic acid usage in patients undergoing femoral fracture surgery.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; | 2018 |
Exclusion criteria and adverse events in perioperative trials of tranexamic acid: a systematic review and meta-analysis.
Topics: Blood Loss, Surgical; Blood Transfusion; Drug Hypersensitivity; Humans; Randomized Controlled Trials | 2019 |
Efficacy of tranexamic acid on operative bleeding in endoscopic sinus surgery: A meta-analysis and systematic review.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Endoscopy; Female; Humans; Incidence; Male; Mi | 2019 |
[Perioperative management of type 2B Von Willebrand's disease in a patient undergoing urgent abdominal surgery].
Topics: Abdomen, Acute; Blood Loss, Surgical; Emergencies; Factor VIII; Female; Heparin, Low-Molecular-Weigh | 2014 |
Does tranexamic acid stop haemoptysis?
Topics: Antifibrinolytic Agents; Benchmarking; Evidence-Based Medicine; Hemoptysis; Humans; Patient Selectio | 2013 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2014 |
Efficiency of tranexamic acid in perioperative blood loss in hip arthroplasty: a systematic literature review and meta-analysis.
Topics: Adolescent; Adult; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Female; | 2015 |
Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cytoreduction Surgical Proc | 2016 |
Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Erythrocyte Transfusion; Hematologic Diseases; Hemorrhag | 2016 |
[Tranexamic acid for upper gastrointestinal bleeding].
Topics: Antifibrinolytic Agents; Gastrointestinal Hemorrhage; Humans; Risk Factors; Thromboembolism; Tranexa | 2016 |
An Evaluation of the Efficacy of Local Hemostatic Measures in Dental Patients Taking Oral Anticoagulants: A Critical Review of the Literature Over the Past Two Decades.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Hemostatic Techniques; Humans; Oral S | 2016 |
What influence do anticoagulants have on oral implant therapy? A systematic review.
Topics: Administration, Oral; Administration, Topical; Anticoagulants; Atrial Fibrillation; Contraindication | 2009 |
Tranexamic acid is associated with less blood transfusion in off-pump coronary artery bypass graft surgery: a systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass, Off-Pump; | 2011 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Humans; Myocardial Infarction; Ran | 2012 |
Antifibrinolytics in orthotopic liver transplantation: current status and controversies.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Humans; Liver Transplantation; Thromboembolis | 2005 |
Antifibrinolytics in liver transplantation.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Humans; Liver Transplan | 2006 |
Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Controlled Cl | 2007 |
Antifibrinolytic therapy: evidence, bias, confounding (and politics!).
Topics: Antifibrinolytic Agents; Aprotinin; Bias; Cardiopulmonary Bypass; Confounding Factors, Epidemiologic | 2007 |
Indications for antifibrinolytic therapy.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Disseminated Intrav | 1975 |
25 trials available for tranexamic acid and Thromboembolism
| Article | Year |
|---|---|
The risk of thromboembolic events with early intravenous 2- and 4-g bolus dosing of tranexamic acid compared to placebo in patients with severe traumatic bleeding: A secondary analysis of a randomized, double-blind, placebo-controlled, single-center trial
Topics: Antifibrinolytic Agents; Double-Blind Method; Hemorrhage; Humans; Thromboembolism; Tranexamic Acid | 2022 |
Tranexamic Acid for Intracerebral Hemorrhage in Patients on Non-Vitamin K Antagonist Oral Anticoagulants (TICH-NOAC): A Multicenter, Randomized, Placebo-Controlled, Phase 2 Trial.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Cerebral Hemorrhag | 2023 |
Tranexamic acid in open aortic aneurysm surgery: a randomised clinical trial.
Topics: Aged; Antifibrinolytic Agents; Aortic Aneurysm; Blood Loss, Surgical; Blood Transfusion; Cardiac Sur | 2020 |
Tranexamic acid in open aortic aneurysm surgery: a randomised clinical trial.
Topics: Aged; Antifibrinolytic Agents; Aortic Aneurysm; Blood Loss, Surgical; Blood Transfusion; Cardiac Sur | 2020 |
Tranexamic acid in open aortic aneurysm surgery: a randomised clinical trial.
Topics: Aged; Antifibrinolytic Agents; Aortic Aneurysm; Blood Loss, Surgical; Blood Transfusion; Cardiac Sur | 2020 |
Tranexamic acid in open aortic aneurysm surgery: a randomised clinical trial.
Topics: Aged; Antifibrinolytic Agents; Aortic Aneurysm; Blood Loss, Surgical; Blood Transfusion; Cardiac Sur | 2020 |
Tranexamic acid to reduce bleeding after dental extraction in patients treated with non-vitamin K oral anticoagulants: design and rationale of the EXTRACT-NOAC trial.
Topics: Administration, Oral; Anticoagulants; Double-Blind Method; Humans; Postoperative Hemorrhage; Thrombo | 2019 |
Topical tranexamic acid in cemented primary total knee arthroplasty without tourniquet: a prospective randomized study.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2020 |
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Aged; Antifibrinolytic Agents; Case-Control Studies; Double-Blind Method; Fema | 2020 |
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Aged; Antifibrinolytic Agents; Case-Control Studies; Double-Blind Method; Fema | 2020 |
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Aged; Antifibrinolytic Agents; Case-Control Studies; Double-Blind Method; Fema | 2020 |
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Aged; Antifibrinolytic Agents; Case-Control Studies; Double-Blind Method; Fema | 2020 |
Comparison of Effects of a Thrombin-Based Hemostatic Agent and Topical Tranexamic Acid on Blood Loss in Patients with Preexisting Thromboembolic Risk Undergoing a Minimally Invasive Total Knee Arthroplasty. A Prospective Randomized Controlled Trial.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement | 2021 |
Tranexamic acid should be avoided for acute gastrointestinal bleeds.
Topics: Antifibrinolytic Agents; Double-Blind Method; Gastrointestinal Hemorrhage; Humans; Thromboembolism; | 2021 |
Synergistic effects of intravenous and intra-articular tranexamic acid on reducing hemoglobin loss in revision total knee arthroplasty: a prospective, randomized, controlled study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2018 |
Benefits of the tranexamic acid in head trauma with no extracranial bleeding: a prospective follow-up of 180 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Component Transfusion; Br | 2019 |
Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery.
Topics: Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inje | 2018 |
Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery.
Topics: Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inje | 2018 |
Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery.
Topics: Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inje | 2018 |
Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery.
Topics: Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inje | 2018 |
Effect of Multiple Doses of Oral Tranexamic Acid on Haemostasis and Inflammatory Reaction in Total Hip Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Oral; Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2019 |
Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial.
Topics: Age Factors; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; B | 2019 |
High-dose (3 g) topical tranexamic acid has higher potency in reducing blood loss after total knee arthroplasty compared with low dose (500 mg): a double-blind randomized controlled trial.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Trans | 2019 |
Topical Administration of Tranexamic Acid Plus Diluted-Epinephrine in Primary Total Knee Arthroplasty: A Randomized Double-Blinded Controlled Trial.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2015 |
Policy of high-dose tranexamic acid for treating postpartum hemorrhage after vaginal delivery.
Topics: Adult; Antifibrinolytic Agents; Female; Ferric Compounds; Ferric Oxide, Saccharated; France; Glucari | 2016 |
Combined Administration of Systemic and Topical Tranexamic Acid for Total Knee Arthroplasty: Can It Be a Better Regimen and Yet Safe? A Randomized Controlled Trial.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2016 |
Combined Intra-Articular and Intravenous Tranexamic Acid Reduces Blood Loss in Total Knee Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2016 |
Combined Intra-Articular and Intravenous Tranexamic Acid Reduces Blood Loss in Total Knee Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2016 |
Combined Intra-Articular and Intravenous Tranexamic Acid Reduces Blood Loss in Total Knee Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2016 |
Combined Intra-Articular and Intravenous Tranexamic Acid Reduces Blood Loss in Total Knee Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2016 |
Peri-articular tranexamic acid injection in total knee arthroplasty: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood T | 2016 |
Peri-articular tranexamic acid injection in total knee arthroplasty: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood T | 2016 |
Peri-articular tranexamic acid injection in total knee arthroplasty: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood T | 2016 |
Peri-articular tranexamic acid injection in total knee arthroplasty: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood T | 2016 |
The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: a comparative study.
Topics: Adult; Aged; Antifibrinolytic Agents; Aprotinin; Double-Blind Method; Female; Fibrinolysis; Hemostat | 2004 |
Oral surgery in patients on oral anticoagulant therapy: a randomized comparison of different INR targets.
Topics: Administration, Oral; Aged; Anticoagulants; Blood Coagulation; Cardiovascular Diseases; Cellulose, O | 2006 |
Effectiveness and safety of tranexamic acid administration during total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
Oral surgery in anticoagulated patients without reducing the dose of oral anticoagulant: a prospective randomized study.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Chi-Square Distributio | 1996 |
A comparative study of the postoperative allogeneic blood-sparing effects of tranexamic acid and of desmopressin after total knee replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2001 |
Tranexamic acid in massive haemorrhage from the upper gastrointestinal tract: a double-blind study.
Topics: Aged; Alcohol Drinking; Blood Transfusion; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Do | 1979 |
50 other studies available for tranexamic acid and Thromboembolism
| Article | Year |
|---|---|
Importance of the Assessment Time Window for Intravenous Tranexamic Acid and Thromboembolic Events.
Topics: Antifibrinolytic Agents; Humans; Thromboembolism; Tranexamic Acid | 2022 |
Importance of the Assessment Time Window for Intravenous Tranexamic Acid and Thromboembolic Events-Reply.
Topics: Antifibrinolytic Agents; Humans; Thromboembolism; Tranexamic Acid | 2022 |
Application of an adjusted patient blood management protocol in patients undergoing elective total hip arthroplasty: towards a zero-percent transfusion rate in renal patients-results from an observational cohort study.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2021 |
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Antifibrinolytic Agents; Hematoma; Humans; Mammaplasty; Thromboembolism; Tranexamic Acid | 2022 |
Clinical outcomes of tranexamic acid in acute hip hemiarthroplasties in frail geriatric patients.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Frail Elderly; | 2022 |
Administration of TXA Is Not Associated with Increased Risk of Thromboembolism, Even in Patients Considered High Risk: Commentary on an article by Steven B. Porter, MD, et al.: "Tranexamic Acid Was Not Associated with Increased Complications in High-Risk
Topics: Antifibrinolytic Agents; Hip Fractures; Humans; Thromboembolism; Tranexamic Acid | 2022 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
The safety of tranexamic acid administration in total knee arthroplasty: a population-based study from Taiwan.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2023 |
Rapid administration of Kcentra® during cardiopulmonary arrest.
Topics: Aged, 80 and over; Anticoagulants; Blood Coagulation Factors; Female; Heart Arrest; Hemorrhage; Huma | 2023 |
Examining the safety profile of a standard dose tranexamic acid regimen in spine surgery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Retrospective Studies; Spine; Thromboe | 2023 |
One Versus Two Doses of Intravenous Tranexamic Acid in Total Knee Arthroplasty.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2021 |
Mortality and Complication Rates in Adult Trauma Patients Receiving Tranexamic Acid: A Single-center Experience in the Post-CRASH-2 Era.
Topics: Adult; Aged; Antifibrinolytic Agents; Female; Hemorrhage; Humans; Injury Severity Score; Male; Middl | 2020 |
Tranexamic acid for severe gastrointestinal bleeding.
Topics: Antifibrinolytic Agents; Double-Blind Method; Gastrointestinal Hemorrhage; Humans; Thromboembolism; | 2020 |
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi | 2020 |
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi | 2020 |
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi | 2020 |
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi | 2020 |
Discussion: Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Antifibrinolytic Agents; Hematoma; Humans; Mammaplasty; Thromboembolism; Tranexamic Acid | 2020 |
Is continuation of anti-platelet treatment safe for elective total hip arthroplasty patients?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Aspirin; Blood Los | 2020 |
In adults with severe acute GI bleeding, tranexamic acid did not reduce death due to bleeding at 5 days.
Topics: Adult; Antifibrinolytic Agents; Double-Blind Method; Gastrointestinal Hemorrhage; Humans; Thromboemb | 2020 |
Is tranexamic acid use in patients with a hip fracture safe?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Denmark; | 2021 |
Safety and Efficacy of Topical Administration of Tranexamic Acid in High-Risk Patients Undergoing Posterior Lumbar Interbody Fusion Surgery.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiovascular Disease | 2021 |
A real-world study of immune thrombocytopenia management during the COVID-19 pandemic in the UK.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Combined M | 2022 |
Combined intravenous, topical and oral tranexamic acid administration in total knee replacement: Evaluation of safety in patients with previous thromboembolism and effect on hemoglobin level and transfusion rate.
Topics: Administration, Intravenous; Administration, Oral; Administration, Topical; Aged; Antifibrinolytic A | 2017 |
Minimizing Blood Loss and Transfusions in Total Knee Arthroplasty.
Topics: Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; Epoetin Alfa; Fibrin Tissu | 2018 |
Intravenous Tranexamic Acid Reduces Postoperative Blood Loss After High Tibial Osteotomy.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Humans; Infusions, Intravenous; Male; Mid | 2018 |
Intravenous Tranexamic Acid Reduces Postoperative Blood Loss After High Tibial Osteotomy.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Humans; Infusions, Intravenous; Male; Mid | 2018 |
Intravenous Tranexamic Acid Reduces Postoperative Blood Loss After High Tibial Osteotomy.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Humans; Infusions, Intravenous; Male; Mid | 2018 |
Intravenous Tranexamic Acid Reduces Postoperative Blood Loss After High Tibial Osteotomy.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Humans; Infusions, Intravenous; Male; Mid | 2018 |
Safety of Tranexamic Acid During Pediatric Trauma: A Nationwide Database Study.
Topics: Acute Kidney Injury; Antifibrinolytic Agents; Case-Control Studies; Child; Child, Preschool; Databas | 2018 |
Tranexamic acid is effective for blood management in open-wedge high tibial osteotomy.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Case-Control Studies | 2018 |
Topical Tranexamic Acid in Revision Total Knee Arthroplasty Reduces Transfusion Rates and May Be Associated With Earlier Recovery.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2019 |
Reducing Blood Loss in Revision Total Hip and Knee Arthroplasty: Tranexamic Acid Is Effective in Aseptic Revisions and in Second-Stage Reimplantations for Periprosthetic Infection.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; | 2018 |
Orthotopic liver transplantation in a patient receiving apixaban for portal vein thrombosis.
Topics: Aged; Blood Loss, Surgical; Carcinoma, Hepatocellular; Dabigatran; Humans; Infusions, Intravenous; L | 2019 |
Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement.
Topics: Administration, Oral; Anticoagulants; Austria; Brain Injuries, Traumatic; Consensus; Dabigatran; Dea | 2019 |
Intraarticular use of tranexamic acid reduces blood loss and transfusion rate after primary total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2019 |
Preliminary results suggest tranexamic acid is safe and effective in arthroplasty patients with severe comorbidities.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplast | 2014 |
Monitoring the anticoagulant effect after a massive rivaroxaban overdose.
Topics: Adult; Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Drug M | 2014 |
Does tranexamic acid alter the risk of thromboembolism after total hip arthroplasty in the absence of routine chemical thromboprophylaxis?
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Case-Control Studies; Female; Hip Joi | 2015 |
Use of Tranexamic Acid Is Associated with Reduced Blood Product Transfusion in Complex Skull Base Neurosurgical Procedures: A Retrospective Cohort Study.
Topics: Antifibrinolytic Agents; Blood Transfusion; Cohort Studies; Erythrocyte Transfusion; Female; Hemoglo | 2016 |
Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid.
Topics: Aged; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replace | 2016 |
Effect of Antifibrinolytic Therapy on Complications, Thromboembolic Events, Blood Product Utilization, and Fusion in Adult Spinal Deformity Surgery.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; | 2016 |
Chemical Thromboprophylaxis Is Not Necessary to Reduce Risk of Thromboembolism With Tranexamic Acid After Total Hip Arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Trans | 2017 |
A comparative, retrospective study of peri-articular and intra-articular injection of tranexamic acid for the management of postoperative blood loss after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Drainage; Female; | 2016 |
Low Risk of Thromboembolic Events After Routine Administration of Tranexamic Acid in Hip and Knee Arthroplasty.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anesthesia; Antifibrinolytic Agents; Arthropla | 2017 |
Intraarticular Administration of Tranexamic Acid is Safe and Effective in Total Knee Arthroplasty Patients at High-Risk for Thromboembolism.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss | 2016 |
The Effectiveness and Safety of Tranexamic Acid in Orthotopic Liver Transplantation Clinical Practice: A Propensity Score Matched Cohort Study.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Databases, Factual; Erythrocyte Transfusion; Female; | 2017 |
Management of a dentigerous cyst in a medically compromised geriatric patient: a case report.
Topics: Aged; Anesthetics, Local; Antifibrinolytic Agents; Aspirin; Bicuspid; Dental Care for Chronically Il | 2012 |
Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty.
Topics: Adult; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2013 |
Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty.
Topics: Adult; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2013 |
Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty.
Topics: Adult; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2013 |
Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty.
Topics: Adult; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2013 |
Oral anticoagulant and dental procedures.
Topics: Administration, Buccal; Anticoagulants; Antifibrinolytic Agents; Clinical Trials as Topic; Humans; M | 2003 |
The use of frusemide and epsilon-amino-caproic-acid in transurethral prostatectomy. a review after 7 years.
Topics: Aged; Aminocaproates; Aminocaproic Acid; Furosemide; Hemorrhage; Humans; Male; Postoperative Complic | 1982 |
[Thromboembolism and eye diseases caused by tranexamic acid].
Topics: Adult; Aged; Cyclohexanecarboxylic Acids; Eye Diseases; Female; Humans; Male; Middle Aged; Thromboem | 1980 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Tranexamic acid reduces blood loss after knee arthroplasty.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Knee Prosthesis; Postoperative Complications; | 1996 |
Management of anticoagulation in patients with prosthetic heart valves undergoing oral and maxillofacial operations.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Heart Valve Prosthesis; Hemorrhage; H | 2000 |
Synthetic antifibrinolytics are not associated with an increased incidence of baffle fenestration closure after the modified Fontan procedure.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Child, Preschool; Echocardiography, Transesophageal; Fon | 2000 |
Effect of infusion of dextran 70 on fibrinolysis inhibition activity in human serum.
Topics: Adolescent; Adult; Aged; Dextrans; Fibrinogen; Fibrinolysis; Fractures, Bone; Humans; Infusions, Par | 1979 |